We do not detect any significant expression of immune checkpoint genes in tumor cells or transitioning populations, including PD-L1 and PD-L2, consistent with the poor response of PDAC to anti-PD-1/PD-L1 immunotherapy74,75. The gene discussed is PDCD1LG2; the disease is neoplasm.